Development At Centessa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions and was well toleratedBOSTON and LONDON, June 05, 2022 (GLOBE NEWSWIRE)

Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions and was well tolerated...

Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting